Nemus Bioscience (NMUS) 4.0000 $NMUS
StockNewsNow.com Publishes New SNNLive Video Interview with NEMUS Bioscience, Inc.
ACCESSWIRE - Wed Feb 11, 7:31AM CST
LOS ANGELES, CA / ACCESSWIRE / February 11, 2015 / StockNewsNow.com, the Official MicroCap News Source, today published an SNNLive Video Interview with John Hollister, CEO of NEMUS Bioscience, Inc. (OTCBB: NMUS), a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics through partnership with the University of Mississippi for the treatment of a variety of diseases or symptoms suffered by many around the globe. The video interview was recorded in San Francisco, CA at the Healthcare Media Day.
NEMUS Bioscience, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Thu Jan 22, 2:01PM CST
COSTA MESA, CA / ACCESSWIRE / January 22, 2015 / NEMUS Bioscience Inc. (OTCQB: NMUS) is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience, Inc. will be presenting at the Cannabis Investor Webcast on Thursday, January 29, 2015 at 2:00 PM ET.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 78.09 (+1.70)
NEMUS Bioscience Announces Appointment of Thomas A. George, CFO of Deckers Brands, to Its Board of Directors
GlobeNewswire - Mon Jan 12, 7:00AM CST
NEMUS Bioscience, Inc. (OTCQB:NMUS) announced the appointment of Thomas (Tom) A. George, current Chief Financial Officer of Deckers Brands (NYSE
ECK), to its Board of Directors. Mr. George will also be responsible for chairing the Company's audit committee. Mr. George has over thirty years of experience in corporate finance and accounting, having served in a number of senior level positions with both public and private companies. Mr. George joined Deckers Brands as Chief Financial Officer in September 2009. Prior to Deckers, Mr. George was with Ophthonix, Inc. where he served as Chief Financial Officer since February 2005. Prior to Ophthonix, Mr. George spent more than seven years as Chief Financial Officer for publicly held Oakley, Inc., now a division of Luxottica Group S.p.A. Earlier in his career, Mr. George held positions at Loral Corporation, International Totalizator Systems, Remec Corporation and Coopers and Lybrand. Mr. George is a graduate of the University of Southern California.
DECK: 77.08 (+0.61)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 78.09 (+1.70)
NEMUS to Move Forward With Cannabinoid-Based Therapy for Open-Angle Glaucoma
GlobeNewswire - Thu Dec 04, 12:05PM CST
NEMUS Bioscience, Inc. (OTC:NMUS) reports that data recently presented at the American Association of Pharmaceutical Scientists (AAPS) meeting in San Diego by Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics, University of Mississippi, showed that a pro-drug formulation of Δ-tetrahydrocannabinol (THC), in-licensed from the University of Mississippi, achieved company goals of significantly lowering intra-ocular pressure (IOP) in an open-angle rabbit glaucoma model.
StockNewsNow.com Publishes New SNNLive Video Interview with NEMUS Bioscience, Inc.
ACCESSWIRE - Wed Feb 11, 7:31AM CST
LOS ANGELES, CA / ACCESSWIRE / February 11, 2015 / StockNewsNow.com, the Official MicroCap News Source, today published an SNNLive Video Interview with John Hollister, CEO of NEMUS Bioscience, Inc. (OTCBB: NMUS), a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics through partnership with the University of Mississippi for the treatment of a variety of diseases or symptoms suffered by many around the globe. The video interview was recorded in San Francisco, CA at the Healthcare Media Day.
NEMUS Bioscience, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Thu Jan 22, 2:01PM CST
COSTA MESA, CA / ACCESSWIRE / January 22, 2015 / NEMUS Bioscience Inc. (OTCQB: NMUS) is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience, Inc. will be presenting at the Cannabis Investor Webcast on Thursday, January 29, 2015 at 2:00 PM ET.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 78.09 (+1.70)
NEMUS Bioscience Announces Appointment of Thomas A. George, CFO of Deckers Brands, to Its Board of Directors
GlobeNewswire - Mon Jan 12, 7:00AM CST
NEMUS Bioscience, Inc. (OTCQB:NMUS) announced the appointment of Thomas (Tom) A. George, current Chief Financial Officer of Deckers Brands (NYSE
ECK), to its Board of Directors. Mr. George will also be responsible for chairing the Company's audit committee. Mr. George has over thirty years of experience in corporate finance and accounting, having served in a number of senior level positions with both public and private companies. Mr. George joined Deckers Brands as Chief Financial Officer in September 2009. Prior to Deckers, Mr. George was with Ophthonix, Inc. where he served as Chief Financial Officer since February 2005. Prior to Ophthonix, Mr. George spent more than seven years as Chief Financial Officer for publicly held Oakley, Inc., now a division of Luxottica Group S.p.A. Earlier in his career, Mr. George held positions at Loral Corporation, International Totalizator Systems, Remec Corporation and Coopers and Lybrand. Mr. George is a graduate of the University of Southern California. DECK: 77.08 (+0.61)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 78.09 (+1.70)
NEMUS to Move Forward With Cannabinoid-Based Therapy for Open-Angle Glaucoma
GlobeNewswire - Thu Dec 04, 12:05PM CST
NEMUS Bioscience, Inc. (OTC:NMUS) reports that data recently presented at the American Association of Pharmaceutical Scientists (AAPS) meeting in San Diego by Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics, University of Mississippi, showed that a pro-drug formulation of Δ-tetrahydrocannabinol (THC), in-licensed from the University of Mississippi, achieved company goals of significantly lowering intra-ocular pressure (IOP) in an open-angle rabbit glaucoma model.
